Search research articles
Contact Us
Filters
Showing results (161-170 of 174) with videos related to
Page
of 18
Sort By:
International Journal of Environmental Research and Public Health
|
January 17, 2020
Environmental Exposures during Puberty: Window of Breast Cancer Risk and Epigenetic Damage
Rama Natarajan, Dana Aljaber, Dawn Au, et al.
Blood
|
June 2, 2019
Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure
Yi-Bin Chen, Nahel Elias, Eliot Heher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 16, 2019
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning
Jeannine S McCune, Tao Wang, Khalid Bo-Subait, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 29, 2005
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
Richard A Nash, Laura Johnston, Pablo Parker, et al.
Clinical Pharmacology and Therapeutics
|
February 10, 2017
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A S Darwich, K Ogungbenro, A A Vinks, et al.
The Oncologist
|
February 19, 2021
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial
Aminah Jatoi, Fang-Shu Ou, Daniel H Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 29, 2019
Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement
Jeannine S McCune, Christine M Quinones, James Ritchie, et al.
The Lancet. Oncology
|
July 3, 2019
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S Bekaii-Saab, Fang-Shu Ou, Daniel H Ahn, et al.
Blood Advances
|
February 5, 2025
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation
Mustafa A Hyder, Dimana Dimitrova, Ruby Sabina, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 26, 2006
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
H Joachim Deeg, Barry E Storer, Michael Boeckh, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 174) with videos related to
Sort By:
Page
of 18
International Journal of Environmental Research and Public Health
|
January 17, 2020
Environmental Exposures during Puberty: Window of Breast Cancer Risk and Epigenetic Damage
Rama Natarajan, Dana Aljaber, Dawn Au, et al.
Blood
|
June 2, 2019
Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure
Yi-Bin Chen, Nahel Elias, Eliot Heher, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 16, 2019
Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning
Jeannine S McCune, Tao Wang, Khalid Bo-Subait, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
June 29, 2005
A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
Richard A Nash, Laura Johnston, Pablo Parker, et al.
Clinical Pharmacology and Therapeutics
|
February 10, 2017
Why has model-informed precision dosing not yet become common clinical reality? lessons from the past and a roadmap for the future
A S Darwich, K Ogungbenro, A A Vinks, et al.
The Oncologist
|
February 19, 2021
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial
Aminah Jatoi, Fang-Shu Ou, Daniel H Ahn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
May 29, 2019
Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement
Jeannine S McCune, Christine M Quinones, James Ritchie, et al.
The Lancet. Oncology
|
July 3, 2019
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Tanios S Bekaii-Saab, Fang-Shu Ou, Daniel H Ahn, et al.
Blood Advances
|
February 5, 2025
Intermediate-dose posttransplantation cyclophosphamide for myeloablative HLA-haploidentical bone marrow transplantation
Mustafa A Hyder, Dimana Dimitrova, Ruby Sabina, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
April 26, 2006
Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
H Joachim Deeg, Barry E Storer, Michael Boeckh, et al.
Page
of 18